Overview
Mirador Therapeutics develops precision therapies for immune-mediated inflammatory and fibrotic diseases. The company uses advanced biology, multi-modal data, and analytics to create treatments that target specific immune pathways involved in these conditions. Its products work by modulating immune responses in a patient-specific way, with data guiding which patients are most likely to benefit from a given therapy. Mirador differentiates itself through its focus on precision medicine and data-driven design, led by former executives from Prometheus Biosciences, and by pursuing partnerships as well as direct commercialization. The goal is to improve patient outcomes by delivering targeted therapies that address the underlying immune mechanisms of inflammation and fibrosis.
Work here?Claim your company
Simplify's take
What believers are saying
- January 2026 raised $250 million, bringing total capital above $650 million.
- Management expects 10-plus clinical readouts by year-end 2027 across Crohn’s, UC, RA, and IPF.
- KP-301 Phase 1 starts by year-end 2026, creating a fresh catalyst and partnering leverage.
What critics are saying
- Mirador has no approved products, so every program depends on 2026-2027 readouts.
- KP-301’s AAV bet enters a crowded complement field against Amgen, Otsuka, and Apellis.
- A single clinical failure or safety signal would destroy IPO optionality and valuation.
What makes Mirador Therapeutics unique
- Mark McKenna rebuilt Mirador in 2024 after Prometheus sold to Merck for $10.8 billion.
- Mirador360 uses 2.5 million molecular profiles to prioritize patients and indications.
- July 2026 KP-301 license adds long-acting complement biology with differentiated dosing.
Help us improve and share your feedback! Did you find this helpful?